Nanobiotechnology is the convergence of existing and new biotechnology with the 1 ability to manipulate matter at or near the molecular level. This ability to manipulate matter on a scale of 100 nanometers (nm) or less is what constitutes the nanotechnology revolution occurring today, the potentially vast economic and social implications of which are yet to be fully understood (Royal Society, 2004). The most immediate way to understand the implications of nanobiotechnology for ethics is to consider the real life concerns of communities that are mobilizing within civil society. The conflicts and ethical debates surrounding nanotechnology will, almost by definition, emerge on the fault lines between different civil society actors, researchers and financial interests associated with nanobiotechnology, as well as (potentially) government regulators. These fault lines are all reflected within the concerns (as expressed d- cursively) of the communities mobilizing. This chapter will explore converging d- courses regarding converging technologies. Converging Technologies (CT) are already a familiar theme in the next gene- tion of biotechnology, nanotechnology, pharmacogenomics and proteomics research 2 and development. Nanobiotechnology means that previously separate disciplines (IT, physics, chemistry, and biology) are merging and converging to create new applications and even new life forms through converged technological platforms. Schummer (2004), and Glimell and Fogelberg (2003, p. 43), note the predominance of interdisciplinarity as a core theme of nano-discourse.

In light of the potential novel applications of neurotechnologies in psychiatry and the current debate on moral bioenhancement, this book outlines the reasons why more conceptual work is needed to inform the scientific and medical community, and society at large, about the implications of moral bioenhancement before a possible, highly hypothetical at this point, broad acceptance, and potential implementation in areas such as psychiatry (e.g., treatment of psychopathy), or as a measure to prevent crime in society. The author does not negate the possibility of altering or manipulating moral behavior through technological means. Rather he argues that the scope of interventions is limited because the various options available to "enhance morality" improve, or simply manipulate, some elements of moral behavior and not the moral agent per se in the various elements constitutive of moral agency. The concept of Identity Integrity is suggested as a potential framework for a responsible use of neurotechnologies in psychiatry to avoid human beings becoming orderers and orderables of technological manipulations.

The Routledge Handbook of the Ethics of Human Enhancement provides readers with a philosophically rich and scientifically grounded analysis of human enhancement and its ethical implications. A landmark in the academic literature, the volume covers human enhancement in genetic engineering, neuroscience, synthetic biology, regenerative medicine, bioengineering, and many other fields. The Handbook includes a diverse and multifaceted collection of 30 chapters—all appearing here in print for the first time— that reveal the fundamental ethical challenges related to human enhancement. The chapters have been written by internationally recognized leaders in the field and are organized into seven parts: Historical Background and Key Concepts Human Enhancement and Human Nature Physical Enhancement Cognitive Enhancement Mood Enhancement and Moral Enhancement Human Enhancement and Medicine Legal, Social, and Political Implications The depth and topical range of the Handbook makes it an essential resource for upper-level undergraduates, graduate students, and postdoctoral fellows in a broad variety of disciplinary areas. Furthermore, it is an authoritative reference for basic scientists, philosophers, engineers, physicians, lawyers, and other professionals who work on the topic of human enhancement.

The financial burden and the level of specialized care required to look after older adults with dementia has reached the point of a public health crisis. Older adults diagnosed and living with the disorder reached 35.6 million worldwide in 2010 and is expected to increase to 135.5 million in 2050, with costs soaring to $1.1 trillion. In the face of the increasing burden this disorder poses to health care systems and the management of this patient population, intelligent assistive technologies (IATs) represent a remarkable and promising strategy to meet the need of persons suffering from dementia. These technologies aim at helping individuals compensate for specific physical and cognitive deficits, and maintain a higher level of independence at home and in everyday activities. However, the rapid development and widespread implementation of these technologies are not without associated challenges at multiple levels. An international and multidisciplinary group of authors provide future-oriented and in-depth analysis of IATs. Part I delineates the current landscape of intelligent assistive technologies for dementia care and age-related disability from a global perspective, while the contributions in Part II analyze and address the major psycho-social implications linked to the development and clinical use of IATs. In the last section, essays examine the major ethical, social and regulatory issues associated with the use of IATs in dementia care. This volume provides an authoritative and comprehensive overview of how IATs are reshaping dementia care.

Nanobiotechnology is the convergence of existing and new biotechnology with the 1 ability to manipulate matter at or near the molecular level. This ability to manipulate matter on a scale of 100 nanometers (nm) or less is what constitutes the nanotechnology revolution occurring today, the potentially vast economic and social implications of which are yet to be fully understood (Royal Society, 2004). The most immediate way to understand the implications of nanobiotechnology for ethics is to consider the real life concerns of communities that are mobilizing within civil society. The conflicts and ethical debates surrounding nanotechnology will, almost by definition, emerge on the fault lines between different civil society actors, researchers and financial interests associated with nanobiotechnology, as well as (potentially) government regulators. These fault lines are all reflected within the concerns (as expressed d- cursively) of the communities mobilizing. This chapter will explore converging d- courses regarding converging technologies. Converging Technologies (CT) are already a familiar theme in the next gene- tion of biotechnology, nanotechnology, pharmacogenomics and proteomics research 2 and development. Nanobiotechnology means that previously separate disciplines (IT, physics, chemistry, and biology) are merging and converging to create new applications and even new life forms through converged technological platforms. Schummer (2004), and Glimell and Fogelberg (2003, p. 43), note the predominance of interdisciplinarity as a core theme of nano-discourse.

Edmund D. Pellegrino has played a central role in shaping the fields of bioethics and the philosophy of medicine. His writings encompass original explorations of the healing relationship, the need to place humanism in the medical curriculum, the nature of the patient's good, and the importance of a virtue-based normative ethics for health care. In this anthology, H. Tristram Engelhardt, Jr., and Fabrice Jotterand have created a rich presentation of Pellegrino's thought and its development. Pellegrino's work has been dedicated to showing that bioethics must be understood in the context of medical humanities, and that medical humanities, in turn, must be understood in the context of the philosophy of medicine. Arguing that bioethics should not be restricted to topics such as abortion, third-party-assisted reproduction, physician-assisted suicide, or cloning, Pellegrino has instead stressed that such issues are shaped by foundational views regarding the nature of the physician-patient relationship and the goals of medicine, which are the proper focus of the philosophy of medicine.